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-Type Natriuretic
eptide and the Stressed Heart*
nju Nohria, MD,
ichael M. Givertz, MD, FACC
oston, Massachusetts
-type natriuretic peptide (BNP) is a member of the
atriuretic peptide family that has physiologic effects includ-
ng diuresis, natriuresis, vasodilation, and antifibrotic activ-
ty. B-type natriuretic peptide also inhibits the renin-
ngiotensin-aldosterone system and lowers endothelin levels
1). It is encoded on chromosome 1 of the human genome
nd is translated into preproBNP, which is cleaved to form
roBNP. The carboxy terminus of proBNP is further
leaved by the serine protease corin to form the biologically
ctive 32-amino acid BNP and the inactive N-terminal
NT) proBNP (2). B-type natriuretic peptide exerts it effects
y binding to the natriuretic peptide A receptor and
ctivating guanylyl cyclase to increase intracellular cyclic
uanosine monophosphate (1). B-type natriuretic peptide is
leared via the natriuretic peptide C receptor and by
nzymatic breakdown by neutral endopeptidase (3).
See page 742
B-type natriuretic peptide is constitutively synthesized
nd secreted by cardiac tissue; however, extracardiac sources,
ncluding the lungs, kidneys, and adrenal glands, also secrete
NP, although at significantly lower levels. Whereas BNP
essenger ribonucleic acid is more abundant in the human
tria than in the ventricles, given the total ventricular mass
0% of all cardiac BNP is derived from the ventricles under
ormal conditions and 88% under pathophysiologic condi-
ions (4). Proximal elements of the BNP promoter are
esponsive to growth and proinflammatory stimuli, resulting
n increased BNP synthesis and secretion under conditions
uch as hypertrophy, ischemic injury, and oxidative stress.
ore distal elements respond to mechanical stretch and
hyroid hormone stimulation, resulting in up-regulation of
NP with increased wall stress as well as during exercise (4).
There is important biologic variability in BNP. B-type
atriuretic peptide is continuously released from the heart,
nd plasma levels in normal individuals increase with age
nd female gender (5). In addition, BNP is metabolized by
dipose tissue, and levels decrease with obesity (6). In 1990,
ukoyama et al. (7) first reported elevated BNP levels in
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.s
From the Cardiovascular Division, Brigham and Women’s Hospital, Boston,
assachusetts.atients with heart failure, and subsequent catheterization
aboratory-based studies demonstrated cardiac release in
ivo (8). Plasma BNP has since emerged as a sensitive and
ost-effective test for the diagnosis of heart failure in
atients presenting with dyspnea of unclear etiology (9).
elevant to patient management, BNP correlates with
everity of symptoms and has been shown to predict
rognosis (9).
Studies in patients with advanced heart failure have
emonstrated that BNP levels correlate modestly with left
entricular filling pressures (10,11), although the diagnostic
ccuracy of BNP for predicting wedge pressure of 15 mm
g is limited by the high number of false negative tests (11).
thers have shown that BNP levels decrease in concert with
reduction in filling pressures during acute diuretic and
asoactive therapy, and discharge BNP has emerged as a
owerful independent predictor of subsequent events
12,13). However, in clinical practice, BNP levels can vary
ubstantially between individuals with the same degree of
eft ventricular dysfunction and similar elevation in filling
ressures. Therefore, the stimuli for BNP secretion in
atients with heart failure remain unclear. In this issue of
he Journal, Iwanaga et al. (14) provide further insight into
otential determinants of BNP secretion that may explain
he observed heterogeneity in BNP levels between individ-
als with heart failure.
In 160 consecutive patients hospitalized with systolic or
iastolic heart failure, Iwanaga et al. (14) measured plasma
NP levels before discharge. They correlated the BNP
easurements with hemodynamic and echocardiographic
arameters of diastolic and systolic load and showed that
NP correlated better with end-diastolic wall stress (r2 
.89) than with any other parameter, including left ventric-
lar end-diastolic pressure (r2  0.33). B-type natriuretic
eptide did not show a significant correlation with left
entricular mass index in their study. In addition, they
emonstrated that despite equivalent end-diastolic filling
ressures, patients with systolic heart failure had higher
nd-diastolic wall stress. They suggest that this correlation
ith wall stress might explain why patients with systolic
eart failure have higher BNP levels than patients with
iastolic heart failure, despite equivalent filling pressures.
hese findings are consistent with those in patients with
ortic stenosis, where end-diastolic wall stress has also been
hown to correlate well with BNP (15).
Chronic elevations in BNP levels are seen with sustained
ressure or volume overload and neuroendocrine stimula-
ion, such as that seen with long-standing hypertension or
hronic heart failure. These situations are characterized by
ctivation of cardiac fetal genes that accompany hypertro-
hy, including re-expression of BNP (16). Left ventricular
ilation is a compensatory response to maintain stroke
olume in heart failure and is directly related to wall stress
y LaPlace’s law. Diastolic overstretch has previously been
hown to promote angiotensin II production, which in turn
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Editorial Comment February 21, 2006:749–51nitiates the early hypertrophic gene response (17). Further-
ore, in isolated papillary muscles, continuous diastolic
verstretch induces BNP expression which is reversed by
reatment with angiotensin-receptor blockade (18). Thus, in
itro data suggests that diastolic overstretch results in
hanges associated with hypertrophy, including increased
NP secretion. The findings of Iwanaga et al. (14)
upport the notion that left ventricular dilation, via its
ffects on wall stress, may be an important mechanical
actor stimulating BNP release in humans with heart
ailure. In fact, their data demonstrates that among other
chocardiographic parameters, left ventricular end-
iastolic diameter and left ventricular end-diastolic vol-
me index were significantly higher in patients with
ystolic dysfunction and greater elevations in BNP.
These findings have important implications for clinical
ractice and future research. First, they suggest that left
entricular end-diastolic wall stress, and perhaps left ven-
ricular dilation may be important stimuli for BNP secre-
ion, and thus BNP may be a marker of ventricular remod-
ling. Although the relationship between end-diastolic wall
tress and outcomes has not been examined, end-systolic
all stress has previously been shown to predict prognosis in
atients with dilated cardiomyopathy (19). Iwanaga et al.
14) found that although both end-systolic and end-
iastolic wall stress correlated with BNP levels, the relation-
hip between end-diastolic wall stress and BNP was more
obust. Thus, it is possible that end-diastolic wall stress is
lso an important predictor of prognosis in heart failure.
Researchers from the Framingham Heart Study have
hown that some of the variability in plasma BNP is
ttributable to genetic effects (20). A recent study evaluating
rst-degree relatives of patients with idiopathic dilated
ardiomyopathy suggests that approximately 10% of asymp-
omatic relatives with echocardiographic evidence of left
entricular enlargement progress to dilated cardiomyopathy
21). One could speculate that genetic variation in BNP
ay contribute to the progression of disease or that elevated
NP levels may identify those individuals with left ventric-
lar dilation who are likely to develop symptomatic disease.
Second, disease-modifying therapy for heart failure, such
s angiotensin-converting enzyme inhibitors, may exert
eneficial effects by decreasing diastolic wall stress (22).
esides conventional medical treatments, there are several
ovel therapies such as the Myocor Myosplint (23) and
orCap cardiac support device (24) that are aimed at
imiting ventricular remodeling and thus reducing end-
iastolic dimensions and wall stress. Other surgical inter-
entions, including left ventricular reconstructive procedures
e.g., aneurysmectomy and surgical ventricular restoration)
nd mitral valve repair, also limit symptoms by reducing
iastolic wall stress (25). Even mechanical cardiac assist has
een shown to decrease wall stress, reverse cardiac hyper-
rophy, and normalize natriuretic peptide levels (26). Given
he tight correlation between plasma BNP levels and end-iastolic wall stress, it is possible that BNP levels could be
sed to monitor the efficacy of these therapies.
Lastly, there is increasing enthusiasm to use BNP to
uide therapy in the outpatient setting. However, target
NP levels remain unclear. Some studies (RABBIT and
TARBRITE) suggest using discharge BNP levels as ther-
peutic targets, because they represent the optimized state,
nd additional elevations are felt to reflect increased filling
ressures. Other studies (27) aim to intensify therapy to an
bsolute target proBNP level of 200 pg/ml, because this
alue is associated with a good prognosis in patients with
nown left ventricular dysfunction (12). The results of this
tudy suggest that in patients with long-standing left ven-
ricular dysfunction and remodeling, left ventricular dilation
nd increased end-diastolic wall stress may be an irreversible
timulus for BNP secretion. Thus therapy targeted to
ndividual patient levels, or targeting a percentage reduction
rom baseline, may be more reasonable than absolute
opulation-based targets. Alternatively, novel biomarkers of
yocardial stress (e.g., ST2) (28) may emerge as more
owerful prognostic indicators or more sensitive and specific
argets for therapy.
Iwanaga et al. (14) have added to the available literature
n stimuli for BNP release in patients with heart failure. By
emonstrating that BNP correlates well with left ventricular
nd-diastolic wall stress they have shown that although
owering filling pressures may help reduce wall stress and
hus BNP, ventricular dilation, by its effects on increasing
nd-diastolic wall stress, may be an independent stimulus
hat is more difficult to modify with therapy. These results
elp explain the persistently elevated and highly variable
NP levels seen in patients with long-standing ventricular
ysfunction and lend support to the notion that BNP may
erve better as a diagnostic and prognostic tool than as a
uide for therapy. However, these results make BNP an
ttractive marker to monitor novel therapies aimed specifi-
ally at limiting ventricular remodeling and reducing end-
iastolic wall stress.
eprint requests and correspondence: Dr. Anju Nohria, Cardio-
ascular Division, Brigham andWomen’s Hospital, 75 Francis Street,
oston, Massachusetts 02115. E-mail: anohria@partners.org.
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